e first quarter of 2008 was $3.7 million
(including a non-cash expense of $191,000 related to stock based
compensation), compared with an operating loss of $2.2 million (including a
non-cash expense of $205,000 related to stock based compensation) for the
corresponding quarter of 2007. Net loss for the first quarter of 2008 was
$3.9 million, or $0.33 per ordinary share, compared with a net loss of $2
million, or $0.23 per ordinary share, for the corresponding quarter of
Research and development expenses of $2.4 million for the first quarter
of 2008, compared to $1.2 million for the first quarter of 2007, remain the
Company's largest expense and accounted for 64% of its operating losses.
As of March 31, 2008 we had $18.6 million in cash, cash equivalents,
short and long term bank deposits and marketable securities. Our outlook of
total cash usage for operating activities for the next nine month of 2008
is approximately $10 million.
As previously announced, the Company continues to receive interest
payments from its auction rate securities, which all but two are rated AAA.
However, due to the continuing uncertainty in the credit market, the
company recorded an impairment of $300,000 during the first quarter.
Rosetta Genomics reports the following scientific and corporate
- Squamous vs. Non Squamous non-small cell lung cancer (NSCLC) -
Columbia University Medical Center's Molecular Pathology Laboratory has
submitted this test, designed to differentiate squamous from non squamous
non-small cell lung cancer (NSCLC) using a single microRNA, for regulatory
approval to the New York State Department of Health. The approval process
is estimated to take 2-6 months.
The ability of physicians to accurately differentiate squamous from
non-squamous NSCLC is an important treatment guide. Bevacizumab, an
angiogenesis inhibitor and an important new modality of therapy for
nPage: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Related biology technology :1
. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 20072
. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma3
. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference4
. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference5
. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 20076
. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 20077
. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer8
. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology9
. Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma10
. Rosetta Genomics Announces Initiation of Expansion of US Operations to Facilitate Expected Product Launches in 200811
. Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer